Cumberland Pharmaceuticals Ranks as one of the Fastest Growing Companies in North America on Deloitte’s 2011 Technology Fast 500

Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) today announced that it has been placed on Deloitte’s 2011 Technology Fast 500list, an annual ranking of the fastest growing technology, media, telecommunications, life sciences and clean technology companies in North America. Rankings are based on percentage of fiscal year revenue growth during the period from 2006 to 2010. Cumberland Pharmaceuticals grew 158% during this period.

“Cumberland Pharmaceuticals, like all 2011 Technology Fast 500 companies, has excelled in fostering innovation and channeling it into spectacular growth against the backdrop of one of the most challenging economies in history,” said Eric Openshaw, vice chairman and U.S. technology, media and telecommunications leader, Deloitte LLP. “Deloitte recognizes Cumberland for its remarkable accomplishment.”

“We are pleased to honor Cumberland Pharmaceuticals as a 2011 Technology Fast 500 company,” said Mark Jensen, managing partner, technology and venture capital services,

Deloitte & Touche LLP. “As one of the fastest growing tech companies in North America, Cumberland has demonstrated excellence in technological innovation, entrepreneurship and rapid growth.”

Cumberland Pharmaceuticals’ Chief Executive Officer, A.J. Kazimi, credits a commitment to providing differentiated products that help improve patient care as the driving force behind the Company’s 158% revenue growth. “We are honored to be recognized  among the innovative companies that comprise the 2011 Technology Fast 500 list,” said Kazimi. “Our ability to deliver consistent revenue growth while providing real solutions for patients is a testament to the dedication and talent of our team. It is extremely rewarding to be honored by Deloitte for the second year in a row.”

About Deloitte’s 2011 Technology Fast 500

Technology Fast 500, which was conducted by Deloitte & Touche LLP, a subsidiary of Deloitte LLP, provides a ranking of the fastest growing technology, media, telecommunications, life sciences and clean technology companies – both public and private – in North America. Technology Fast 500 award winners are selected based on percentage fiscal year revenue growth from 2006 to 2010. In order to be eligible for Technology Fast 500 recognition, companies must own proprietary intellectual property or technology that is sold to customers in products that contribute to a majority of the company’s operating revenues.

Companies must have base-year operating revenues of at least $50,000 USD or CD, and current-year operating revenues of at least $5 million USD or CD. Additionally, companies must be in business for a minimum of five years, and be headquartered within North America.

Rick Greene named CFO of Cumberland Pharmaceuticals

Nashville-based Cumberland Pharmaceuticals Inc.    (Nasdaq: CPIX) has named Rick Greene as its new chief financial officer.

According to a news release, Greene has served as the company’s interim vice president of finance and accounting since April.

Greene previously served as CFO for Surgical Alliance Corp. and as director of financial operations at Phycor Inc. He has also held positions with accounting firms Ernst & Young    and Crowe Horwath    .

“Rick is uniquely qualified to help drive growth and operational excellence at Cumberland,” said A.J. Kazimi, CEO of Cumberland Pharmaceuticals, in a news release. “In addition to a deep knowledge of our operations, he brings extensive experience in health care financial management and accounting that will be key to our company’s continued success.”

Tennessee ECD $100,000 Grant Announced

(Nashville, Tennessee) – November 26, 2002

Tony Grande, state commissioner of the Department of Economic and Community Development (ECD), today announced that funding has been approved for a $100,000 Tennessee Industrial Infrastructure Program (TIIP) grant in support of Cumberland Emerging Technologies (CET).

CET is a joint initiative between the Tennessee Technology Development Corp. (TTDC), Vanderbilt University and Cumberland Pharmaceuticals Inc. The mission of CET is to bring biomedical technologies and products conceived at Tennessee research centers to the commercial marketplace.

“We are very pleased to support this innovative partnership. We want the world to know that ‘Tennessee Means Technology’, as we step up our efforts to grow and attract the New Economy jobs of the future,” Grande said. “Nothing will be more important to the future of our great state over the next 20 years than our science and technology assets and the new higher-paying jobs and new business success stories they help create.”

The grant will be used to assist with wet lab infrastructure at CET’s new life sciences incubator facility. In July, CET signed a lease accessing up to 20,000 square feet in Gateway Pavilion, adjacent to the Union Station Hotel in downtown Nashville, for this laboratory facility. For more information on CET, please visit

“With the support of the state, CET combines the strength of our partners in TTDC and Vanderbilt to provide universities, hospitals and other research organizations with needed commercial development infrastructure and access to federal funding for innovation and technology transfer,” said A.J. Kazimi, CEO of Cumberland Pharmaceuticals Inc.

“The CET grant is a great example of how we as a state are getting aggressive and looking for new ways to dedicate resources to technology and biotech development in Tennessee, in order to grow the jobs of tomorrow and remain competitive in the life science sector,” Grande added.

The Tennessee Industrial Infrastructure Program (TIIP) was authorized by the Tennessee General Assembly in 1988. The program is administered by ECD. TIIP funds are to be used for infrastructure improvements or for job-specific workforce training for Tennessee industry. For more information on the program, please visit the ECD website at

CET signs Nano Delivery as first tenant for Life Sciences Facility

(Nashville, Tennessee) – August 5, 2002

Cumberland Emerging Technologies (CET) and NanoDelivery, Inc. (NDI) have signed an agreement making NDI the first official tenant in CET’s new downtown life sciences facility. Last month CET signed a lease accessing up to 20,000 square feet in downtown Nashville, adjacent to the Union Station Hotel, for development of this laboratory facility.

NDI was established by Ales Prokop, Ph.D., a research professor at Vanderbilt University’s Department of Chemical Engineering. The company currently specializes in water-soluble nanotechnology for drug, gene and antigen delivery and vascularization.

“Our rationale to relocate NDI to the new CET facility was twofold,” said Dr. Prokop. “The proximity to Vanderbilt University is a major benefit, and we look forward to collaboration with CET on technologies relevant to its core pharmaceutical interests.”

“We are pleased to welcome NDI as a tenant for our new facility,” said A.J. Kazimi, CEO of Cumberland Pharmaceuticals. “Dr. Prokop’s background in both Chemical Engineering and Applied Microbiology has led to his working at the interface between life sciences and engineering. NDI is capable both of developing novel technologies at the laboratory scale, and initiating the studies necessary for successful commercialization of its development work.”

NDI’s research is the subject of several granted patents and pending applications both through Vanderbilt and the company itself. A portion of the work is also the subject of funding proposals for collaborative development work between CET and NDI.

Cumberland Emerging Technologies Inc (CET) is a joint initiative between Vanderbilt University, Cumberland Pharmaceuticals Inc, and the Tennessee Technology Development Corporation (TTDC). The mission of CET ( is to bring biomedical technologies and products conceived at Vanderbilt and other Tennessee research centers to the commercial marketplace. CET manages the development and commercialization process for select projects, and provides critical expertise on intellectual property, regulatory, manufacturing, and marketing issues that are critical to successful new biomedical products. This expertise is available also for future tenants in CET’s facility.